- First Online:
- 19 Downloads
Fluvoxamine facilitates serotoninergic neurotransmission via potent and selective inhibition of serotonin (5-hydroxytryptamine; 5-HT) reuptake into presynaptic neurones.
The overall antidepressant efficacy of fluvoxamine 100 to 300 mg/day for 4 to 6 weeks in once daily or divided dosage regimens appears to be at least comparable to that of imipramine and similar to that of clomipramine, dothiepin, desipramine, amitriptyline, lofepramine, maprotiline, mianserin and moclobemide. The efficacy of fluvoxamine has been maintained for up to 1 year, but long term data are limited, and there are no comparative studies of fluvoxamine with other selective serotonin reuptake inhibitors. In some studies, fluvoxamine appeared to have an earlier beneficial effect on suicidal ideation and/or anxiety or somatic complaints compared with imipramine, dothiepin and maprotiline.
Gastrointestinal adverse effects, especially nausea, are commonly reported with fluvoxamine but are generally mild to moderate in severity. The tolerability profile of fluvoxamine appears to be more favourable than that of tricyclic antidepressants in terms of cardiotoxic and anticholinergic adverse effects, sedation, weight gain and death from overdosage.
Thus, fluvoxamine is an effective and well tolerated antidepressant agent that is becoming established as an alternative to older agents in patients with mild, moderate or severe depression. Fluvoxamine may be particularly beneficial in potentially suicidal patients with severe depression, in those with an underlying compulsive personality or cardiovascular disorder, in patients with coexistent anxiety or agitation, and in the elderly.
In vitro and in vivo studies in animals and humans have demonstrated that fluvoxamine facilitates serotoninergic neurotransmission by potent and specific inhibition of presynaptic neuronal reuptake of serotonin (5-hydroxytryptamine; 5-HT). Single-dose administration of fluvoxamine significantly reduced serotonin turnover in rat brain, and histochemical studies demonstrated that fluvoxamine increases extraneuronal concentrations of serotonin in the raphé nucleus and frontal cortex, and decreases intraneuronal concentrations of serotonin in the raphé nucleus. In contrast, fluvoxamine generally has no effect on noradrenergic and dopaminergic mechanisms. In vitro radioligand binding studies have demonstrated that fluvoxamine, like other selective serotonin reuptake inhibitors, has little or no affinity for α1, α2, β, dopamine D2, histamine H1, 5-HT1, 5-HT2 or muscarinic receptors. Fluvoxamine does not appear to inhibit monoamine oxidase.
Studies in animals and humans have shown relatively few cardiovascular effects with fluvoxamine, and suggest that it is less likely to produce adverse cardiovascular effects than tricyclic antidepressants. Trials in healthy human volunteers have confirmed the results of in vitro and in vivo studies in animals which suggested that fluvoxamine is unlikely to cause anticholinergic effects. In contrast with other antidepressant agents such as tricyclic antidepressants, mianserin and maprotiline, fluvoxamine did not exhibit pro-convulsive effects in animal models of epilepsy, except at very high doses (⩾ 100 mg/kg intraperitoneally). Electroencephalographic and psychometric tests in healthy humans suggest that fluvoxamine is less sedating than imipramine or mianserin.
Fluvoxamine is well absorbed following oral administration to healthy volunteers, and peak plasma concentrations are achieved within approximately 2 to 8 hours. Food does not significantly affect the rate or extent of absorption. Mean elimination half-life (t½) is approximately 19 and 22 hours after single and multiple doses, respectively, and is not significantly increased in the elderly. Fluvoxamine undergoes extensive hepatic metabolism to at least 11 metabolites; however, none of these is likely to possess psychotropic activity. More than 90% of a dose is eliminated in the urine as metabolites, with ⩽ 4% of a dose eliminated in the urine as unchanged drug. Increases in mean area under the plasma concentration-time curve and t½ values (by up to 64%) were noted in patients with biopsy-proven liver cirrhosis compared with healthy volunteers receiving singledose fluvoxamine, suggesting the need for dosage adjustment in patients with hepatic impairment. Pharmacokinetic parameters of fluvoxamine in the elderly appear similar to those in younger volunteers, although data are limited.
Results from several double-blind comparative trials indicate that fluvoxamine 100 to 300 mg/day is at least as effective as imipramine in patients with mainly moderate to severe major depression. Hamilton Depression Rating Scale (HDRS) scores were reduced by 28 to 75% (mean 37.6%) with fluvoxamine, by 28 to 55% (mean 39%) with imipramine and by 6 to 37% (mean 27%) with placebo after 4 to 6 weeks’ treatment. Corresponding reductions in Clinical Global Impression (CGI) scores were 29 to 68%, 23 to 52% and 21 to 28.5%. The therapeutic efficacy of fluvoxamine appears to be similar to that of clomipramine, dothiepin, desipramine, lofepramine, amitriptyline, maprotiline, mianserin and moclobemide. Although improvements in HDRS, CGI and Montgomery-Åsberg Depression Rating Scale scores with fluvoxamine have been maintained in the long term (up to 1 year), such data are limited. Results from individual studies should be interpreted with caution because of significant placebo effects (as is common with all antidepressant trials), small numbers of patients and inconsistencies in the demonstration of the known superior efficacy of fluvoxamine and other antidepressant agents over placebo in some studies.
The onset of antidepressant effect with fluvoxamine appears to be similar to that of standard antidepressant agents. However, results from some studies suggest that fluvoxamine may have an earlier beneficial effect on suicidal ideation and/or anxiety or somatic complaints compared with imipramine, dothiepin and maprotiline.
Limited data suggest that fluvoxamine may be more effective in patients with severe rather than mild or moderate depression, and results from 1 study suggest that fluvoxamine may be particularly effective in patients with an underlying compulsive personality. Evidence suggests that the efficacy of fluvoxamine in elderly patients with depressive illness is similar to that in younger patients. Responses to fluvoxamine in patients refractory to standard antidepressants have been reported.
Fluvoxamine in dosages of 50 to 300 mg/day has been generally well tolerated by patients with depressive illness in short (4 to 6 weeks) and long (up to 48 weeks) term clinical trials.
Gastrointestinal disturbances are the most common adverse effects associated with fluvoxamine, with the incidence of nausea ranging from ≈ 16 to 37%. These adverse effects appear to be mild to moderate in severity; the effect of meal times on the incidence of these adverse effects has not been reported. Pooled data from postmarketing surveillance studies involving more than 34 000 patients (most of whom had depression) showed nausea to be the most common adverse effect associated with fluvoxamine therapy (15.7%), followed by somnolence (6.4%) and asthenia (5.1%).
The overall tolerability profile of fluvoxamine appears to be more favourable than that of tricyclic antidepressants, being devoid of clinically significant anticholinergic or cardiotoxic adverse effects, sedation or weight gain.
Overall incidence rates of fluvoxamine-associated adverse effects in the elderly are similar to those in younger patients. However, more elderly than younger patients withdrew from fluvoxamine treatment because of adverse effects.
Although fluvoxamine is thought to have less epileptogenic potential than tricyclic antidepressants, possible fluvoxamine-induced seizures have been reported. There have been no reports of fluvoxamine-associated increases in suicidal ideation or aggressive behaviour. Increases in liver enzyme levels during fluvoxamine treatment have been reported although no other clinically significant changes in laboratory parameters have been observed. Fluvoxamine is relatively safe in overdosage; in over 300 reports of fluvoxamine overdosage (up to 10g), there has been only 1 reported death attributable to fluvoxamine alone.
Dosage and Administration
The effective dosage of fluvoxamine in patients with depression usually varies between 100 and 200 mg/day. The dosage should be adjusted according to individual response, and some patients may require up to 300 mg/day. The minimum effective starting dosage is 100 mg/day administered at night; dosages > 100 mg/day should be given in divided doses. An initial dosage of 50 mg/day for 1 week may minimise nausea.
Reduced dosages are recommended in patients with hepatic or renal insufficiency, and careful laboratory monitoring, particularly during the first month of treatment, is advised. Dosage adjustments appear to be unnecessary in the elderly although fluvoxamine should be titrated slowly during the initial stages of therapy.
Fluvoxamine inhibits cytochrome P450IICg/IA2-mediated N-demethylation of various tricyclic antidepressants but, in contrast with fluoxetine, paroxetine and sertraline, has minimal inhibitory effects on cytochrome P-450IID6-catalysed hydroxylation of these agents. Fluvoxamine should be avoided in patients with a history of epilepsy. Caution is also recommended with the concomitant administration of fluvoxamine and lithium, theophylline or warfarin. Fluvoxamine should not be administered with, or within 2 weeks of, treatment with a monoamine oxidase inhibitor, and a monoamine oxidase inhibitor should not be initiated within 1 week after stopping fluvoxamine therapy.
Unable to display preview. Download preview PDF.
- Amin MM, Ananth JV, Coleman BS, Darcourt G, Farkas T, et al. Fluvoxamine: antidepressant effects confirmed in a placebo-controlled international study. Clinical Neuropharmacology & (Suppl. 1): 312–319, 1984Google Scholar
- Amore M, Bellini M, Berardi D, Berlinzani L, Cervino G, et al. Double-blind comparison of fluvoxamine and imipramine in depressed patients. Current Therapeutic Research 46: 815–820, 1989Google Scholar
- Anon. Fluvoxamine prescribing information, The Netherlands, 1991Google Scholar
- Baldessarini RJ. Overview of recent advances in antidepressant pharmacology: part II. McLean Hospital Journal 7 (1): 1–27, 1982Google Scholar
- Barrelet L, Blajev B, Bolzani L, de Saussure Ch, Kasas A, et al. Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in in- and outpatients with a severe depressive episode. Schweizerische Rundschau fur Medizin/Praxis 80: 524–528, 1991Google Scholar
- Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse, in press, 1993Google Scholar
- Benazzi F, Mazzoli M. Polydipsia induced by fluvoxamine. Correspondence. Pharmacopsychiatry 26: 63, 1993Google Scholar
- Bougerol T, Uchida C, Gachoud J-P, Köhler M, Mikkelsen H. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM-III). Psychopharmacology 106 (Suppl.): 102–108, 1992Google Scholar
- Bradford LD. Preclinical pharmacology of fluvoxamine (Floxyfrol). Proceedings of the international symposium on fluvoxamine, Amsterdam, September 8–9, 1983, pp. 13–17, 1984Google Scholar
- Cassano G, Conti L. Preliminary results: placebo-controlled data on fluvoxamine maleate, a serotonergic antidepressant. Clinical Neuropharmacology 7 (Suppl. 1): S312–319, 1984Google Scholar
- Cialdella E. Fluvoxamine in the management of depressive patients. Gazette Medicale 98: 43–47, 1991Google Scholar
- Conti L, Dell’osso L, Re F, Musetti L, Cassano GB. Fluvoxamine maleate: double-blind clinical trial vs placebo in hospitalised depressed patients. Current Therapeutic Research 43:468–480,1988Google Scholar
- DeBree H, Van der Schoot JB, Post LC. Fluvoxamine maleate; disposition in man. European Journal of Drug Metabolism and Pharmacokinetics 8: 175–179, 1983Google Scholar
- Deerling R, Rees-Jones DI, Simmons R, Ashford J. Rising-dose fluvoxamine therapy in depression; an overview of two clinical studies. European Neuropsychopharmacology 2(3): 302, 1992Google Scholar
- Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, et al. Serotonin function and the mechanism of antidepressant action. Archives of General Psychiatry 47: 411–418Google Scholar
- Demisch K, Demisch L, Bochnik HJ, Nickelsen T, Althoff PH, et al. Melatonin and cortisol increase after fluvoxamine. Correspondence. British Journal of Clinical Pharmacology 22: 620–622, 1986Google Scholar
- De Wilde JE, Mertens C, Wakelin JS. Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing. British Journal of Clinical Pharmacology 15 (Suppl): 427–431, 1983Google Scholar
- Diot P, Jonville AP, Gerard F, Bonnelle M, Autret E, et al. Possible interaction entre théophylline et fluvoxamine. Therapie 46: 169–171. 1991Google Scholar
- Dresse A, Scuvee-Moreau J. The effects of various antidepressants on the spontaneous firing rates of noradrenergic and serotonergic neurons. Clinical Neuropharmacology 7 (Suppl. 1): S312–319, 1984Google Scholar
- Eckardt MJ, Stapleton JM, Rio D, et al. Interactions of fluvoxamine and ethanol in healthy volunteers. Clinical Neuropharmacology 9 (Suppl.) 4: 55–57, 1986Google Scholar
- Fabre L, Vettraine J, Birkhimer L, Houser V. Fluvoxamine in the treatment of depression: a double-blind comparison with imipramine and placebo in outpatients with major depression. CINP Meeting, Nice, France, 1992Google Scholar
- Faverin Product Monograph. A review of pharmacological and clinical properties. Duphar Laboratories, Southampton, 1992Google Scholar
- Feighner JP, Boyer WF, Meredith CH, Hendrickson GG. A placebocontrolled inpatient comparison of fluvoxamine maleate and imipramine in major depression 4: 239–244, 1989Google Scholar
- Fleishaker JC, Hulst LK. Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers. Abstract. Pharmaceutical Research 9 (Suppl.): S292, 1992Google Scholar
- Gaszner P. Fluvoxamine treatment of depressive disorders. Abstract. European Journal of Pharmacology 183: 1910, 1990Google Scholar
- Gonella G, Baignoli G, Ecari U. Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study 12: 177–184, 1990Google Scholar
- Guelfi JD, Dreyfus JF, G.E.P.E.C.E.P. Fluvoxamine: efficacy and tolerance of a new antidepressant in a large multicentre study. Clinical Neuropharmacology 7 (Suppl. 1): S312–319, 1984Google Scholar
- Guelfi JD, Sutet P. Long-term study of fluvoxamine versus clomipramine. 18th C.I.N.P Congress, Nice, France, June 28-July 2, 1992Google Scholar
- Hansten PD, Horn JR (Eds). Drug Interactions and Updates, Lea & Febiger, Malvern, Pennsylvania, 1990Google Scholar
- Harris B, Ashford J. Maintenance antidepressants and weight gain: a comparison of fluvoxamine and amitriptyline. British Journal of Clinical Research 2: 81–88, 1991Google Scholar
- Harris B, Szulecka TK, Anstee JA. Fluvoxamine versus amitriptyline in depressed hospital out-patients: a multicentre double-blind comparative trial. British Journal of Clinical Research 2: 89–99, 1991Google Scholar
- Hendrickx B, Floris M. A controlled pilot study of the combination of fluvoxamine and lithium. Current Therapeutic Research 49: 106–110, 1991Google Scholar
- Karege F, Bovier Ph, Gaillard J-M, Tissot R. Plasma MHPG and AMDP depression relations, evolution and drug effect in a followup study of depressed patients. Human Psychopharmacology 6: 11–17, 1991Google Scholar
- Kasper S, Dötsch M, Vieira A. Plasma levels of fluvoxamine and maprotiline and clinical response in major depression. Abstract. Pharmacopsychiatry 25: 106, 1992Google Scholar
- Lapierre YD, Oyewumi LK, Coleman B. The efficacy of fluvoxamine as an antidepressant. Clinical Trials Journal 18: 313–320, 1981Google Scholar
- Linnoila M, Stapleton JM, George DT, Lane E, Eckardt MJ. Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. Journal of Clinical Psychopharmacology 13: 175–180, 1993PubMedGoogle Scholar
- McHardy KSyndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy. British Journal of Clinical Pharmacology 47: 62–63, 1993Google Scholar
- Müller-Oerlinghausen B, Rao ML, Stieglitz RD, Volz HP. Fluvoxamine challenge test, phototherapy, and successive fluvoxamine treatment in patients with non-seasonal depression. Pharmacopsychiatry 22: 209–210, 1989Google Scholar
- Mullin JM, Pandita-Gunawardena VR, Whitehead AM. A doubleblind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder 42: 51–55, 1988Google Scholar
- Nestler EJ, McMahon A, Sabban EL, Tallman JF, Duman RS. Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proceedings of the National Academy of Science 87: 7522–7526, 1990Google Scholar
- Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, et al. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatrica Scandinavica 78: 668–675, 1988PubMedGoogle Scholar
- Ottevanger EA. Fluvoxamine activity profile with special emphasis on the effect on suicidal ideation. European Journal of Clinical Research 1:47–54, 1991bGoogle Scholar
- Ottevanger EA. The efficacy of fluvoxamine in patients with severe depression. British Journal of Clinical Research 2: 125–132,1991aGoogle Scholar
- Paunovic VR, Jasovic-Gasic M, Timotijevic I. Serotonergic control of behaviour: fluvoxamine and suicidal syndrome. Iugoslavica Physiologica Pharmacologica Acta 25: 403–409, 1989Google Scholar
- Phanjoo A. The elderly depressed and treatment with fluvoxamine. International Clinical Psychopharmacology 6 (Suppl.): 33–39Google Scholar
- Poeldinger W, Bures E. Fluvoxamine in patients with depressive disorder. Proceedings of the International Symposium on Fluvoxamine, Amsterdam, September 8–9, 1983, p 13–17, 1984Google Scholar
- Prager G, Cimander K, Wagner W, Schnitker J, Koch H-F. The cardiotropic effect of antidepressants. Advances in Pharmacotherapy 2: 133–150, 1986Google Scholar
- Prager G, Stollmaier W, Prager R, Koch H-F, Wagner W, et al. Sicherheit ubd Verträglichkeit von fluvoxamin bei kardialen risikopatienten. In German. TW Neurologie Psychiatrie 5: 548–562, 1991Google Scholar
- Racagni G, Bradford D. Biochemical and behavioural changes on chronic fluvoxamine administration. 14th CINP, Florence, Italy, 1984Google Scholar
- Raghoebar M, Roseboom H. Kinetics of fluvoxamine in special populations. Poster. Symposium on variability in pharmacokinetics and drug response. Gothenburg, Oct 3–5, 1988Google Scholar
- Rickeis K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. Journal of Clinical Psychiatry 51 (Suppl): 9–12, 1990Google Scholar
- Robertson MM, Trimble MR. Depressive illness in patients with epilepsy: a review. Epilepsia 24 (Suppl 2): 109–116, 1983Google Scholar
- Roos JC, Sharp DJ. Antidepressant drugs and cardiovascular side effects. A comparison of fluvoxamine and the tricyclic antidepressant drugs. In Burrows et al. (Eds) Biological psychiatry: recent studies, John Libbey, London & Paris, 1984Google Scholar
- Spina E, Avenoso A, Pollicano AM, Fazio A, Pisani F, et al. No effect of fluvoxamine or fluoxetine on plasma concentrations of carbamazepine in epileptic patients. Pharmacological Research 25 (Suppl. 2)214–215, 1992Google Scholar
- Stollmaier W, Cimander KF, Wagner W. Efficacy and tolerance of fluvoxamine (Fevarin®) in depressive syndromes in the practice. The results of a multicentred study on 2296 patients [Translated into English from German]. Nervenheilkunde 8: 247–252, 1989Google Scholar
- Thomson AH, McGovern EM, Bennie P, Caldwell G, Smith M. Interaction between fluvoxamine and theophylline. Correspondence. Pharmaceutical Journal 249: 137, 1992Google Scholar
- Van Harten J, Holland RL, Wesnes K. Influence of multiple-dose administration of fluvoxamine on the pharmacokinetics of the benzodiazepines bromazepam and lorazepam: a randomised, cross-over study. Abstract. European Neuropsychopharmacology 2: 381, 1992bGoogle Scholar
- Van Harten J, Holland RL, Wesnes K, Raghoebar M. Kinetic and dynamic interaction study between fluvoxamine and benzodiazepines. Poster presented at the Second Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology, Jerusalem, May 24–29, 1992cGoogle Scholar
- Van Harten J, Van Bemmel P, Dobrinska MR, Ferguson RK, Raghoebar M. Bioavailability of fluvoxamine given with and without food. Biopharmaceutics and Drug Disposition 12: 571–576, 1991Google Scholar
- Wagner W, Cimander K, Schnitker J, Koch H-F. Influence of concomitant psychotropic medication on the efficacy and tolerance of fluvoxamine. Advances in Pharmacotherapy 2: 34–56, 1986Google Scholar
- Wagner W, Zaborny BA, Gray Fluvoxamine. A review of its safety profile in worldwide studies. Submitted for publication, 1993Google Scholar
- Wils V. Extrapyramidal symptoms in a patient treated with fluvoxamine. Journal of Neurology, Neurosurgery and Psychiatry 55:330–331, 1992Google Scholar
- Wright JH, Denber HCB. Clinical trial of fluvoxamine: a new serotonergic antidepressant. Current Therapeutic Research 23: 83–89,1978Google Scholar